← TransMedics Group, Inc.
| Annual Trend | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | ($23.8m) |
($33.5m)
-41.21%
|
($28.7m)
+14.31%
|
($44.2m)
-53.80%
|
($36.2m)
+18.06%
|
($25.0m)
+30.92%
|
$35.5m
+241.70%
|
$190.3m
+436.58%
|
— | |
| Depreciation and amortization expense | $769k | $1.2m | $1.6m | $1.8m | $3.5m | $8.2m | $19.8m | $27.2m | $36.4m | |
| Deferred taxes | — | — | — | — | — | ($1.7m) | — | ($83.5m) | — | |
| Stock-based compensation expense | $144k | $854k | $2.4m | $6.9m | $10.3m | $19.8m | $33.2m | $36.9m | $37.1m | |
| Accounts receivable | ($2.5m) | ($3.2m) | ($218k) | $840k | ($21.7m) | ($33.8m) | ($34.3m) | $13.9m | $618k | |
| Inventory | ($2.7m) | ($4.1m) | ($1.7m) | ($4.9m) | ($8.0m) | ($28.1m) | ($8.4m) | ($7.7m) | ($23.7m) | |
| Transfers of inventory to property, plant and equipment | $1.4m | $2.1m | $1.2m | $1.8m | $2.1m | $4.6m | $5.8m | $5.7m | — | |
| Accounts payable | $164k | $3.4m | ($5.8m) | $5.1m | ($3.3m) | $7.0m | ($1.4m) | ($19k) | $3.1m | |
| Purchases of property, plant and equipment included in accounts payable and accrued expenses | — | $169k | — | $1.2m | $62k | $2.5m | $2.1m | $1.8m | — | |
| Accrued expenses and other current liabilities | $2.3m | $2.5m | $1.9m | $4.9m | $3.4m | $14.2m | $7.9m | $17.7m | — | |
| Deferred revenue | $67k | ($136k) | $60k | $7k | — | $83k | ($203k) | $1.1m | — | |
| Prepaid expenses and other current assets | ($1.4m) | $250k | ($769k) | ($3.2m) | $2.5m | ($2.1m) | ($6.3m) | ($3.8m) | — | |
| Net cash provided by (used in) operating activities | ($26.0m) |
($32.3m)
-24.25%
|
($30.3m)
+6.26%
|
($28.9m)
+4.63%
|
($45.8m)
-58.73%
|
($13.0m)
+71.57%
|
$48.8m
+474.60%
|
$192.8m
+295.14%
|
$145.9m
-24.33%
|
|
| Purchases of property, plant and equipment | ($418k) | ($165k) | ($455k) | ($3.5m) | ($11.9m) | ($151.8m) | ($129.7m) | ($59.3m) | — | |
| Net cash used in investing activities | $12.3m | ($60.5m) | ($41.6m) | $29.3m | $54.5m | ($194.0m) | ($129.3m) | ($59.3m) | ($66.9m) | |
| Proceeds from issuance of common stock upon exercise of stock options | $46k | $202k | $227k | $974k | $4.7m | $6.2m | $20.8m | $13.7m | $0 | |
| Proceeds from issuance of common stock in connection with employee stock purchase plan | — | — | $357k | $419k | $509k | $955k | $2.1m | $3.2m | $0 | |
| Conversion of convertible senior notes into common stock | — | — | — | — | — | — | $4k | — | — | |
| Net cash provided by financing activities | $22.1m |
$92.7m
+320.25%
|
$75.5m
-18.52%
|
$1.4m
-98.16%
|
$167.9m
+11955.06%
|
$400.4m
+138.45%
|
$22.9m
-94.29%
|
$16.9m
-26.30%
|
$11.5m
-31.95%
|
|
| Net increase (decrease) in cash and restricted cash | $8.3m | ($149k) | $4.5m | $999k | $175.6m | $193.6m | ($58.2m) | $151.7m | — | |
| Cash and restricted cash, beginning of period | $20.7m | $20.6m | $25.1m | $26.1m | $201.7m | $395.3m | $337.1m | $488.9m | — | |
| Effect of exchange rate changes on cash and restricted cash | ($82k) | ($85k) | $803k | ($797k) | ($1.0m) | $193k | ($536k) | $1.3m | ($475k) | |
| Restricted Cash | — | $500k | $500k | $500k | $500k | $500k | $500k | $500k | — | |
| Additional Supplementary Disclosures | ||||||||||
| Additional Supplementary Disclosures | ||||||||||
| Acquired in-process research and development expenses | — | — | — | — | — | $27.2m | — | — | — | |
| Non-cash interest expense and end of term accretion expense | $177k | $475k | $511k | $540k | $465k | $2.1m | $3.1m | $3.1m | — | |
| Non-cash lease expense | — | — | — | $829k | $717k | $1.0m | $1.6m | $2.1m | — | |
| Unrealized foreign currency transaction (gains) losses | $150k | $200k | ($1.1m) | $928k | $1.1m | ($342k) | $665k | ($1.6m) | — | |
| Loss on disposal of fixed assets | — | — | — | — | — | — | $17k | $80k | — | |
| Other non-current assets | — | — | — | — | — | ($54k) | ($149k) | ($23k) | — | |
| Operating lease liabilities | — | — | — | $236k | $255k | ($1.6m) | ($2.3m) | ($2.9m) | — | |
| Purchase of business, net of cash acquired | — | — | — | — | — | ($14.9m) | $441k | — | — | |
| Proceeds from issuance of convertible senior notes, net of issuance costs paid of $14,620 | — | — | — | — | — | $445.4m | — | — | — | |
| Purchases of capped calls related to convertible senior notes | — | — | — | — | — | ($52.1m) | — | — | — | |
| Tax withholding payments related to net settlement of restricted stock units | — | — | — | — | — | — | — | ($138k) | — | |
| Cash paid for interest | $2.4m | $3.9m | $3.5m | $3.3m | $3.3m | $8.1m | $11.3m | $10.7m | — | |
| Operating lease liabilities arising from obtaining right-of-use assets | — | — | — | — | — | $2.2m | $1.5m | $795k | — | |
| Cash and cash equivalents | — | $20.1m | $24.6m | $25.6m | $201.2m | $394.8m | $336.6m | $488.4m | $401.1m |